Comparative Efficacy of Combined Finerenone and Conventional-Dose ARB vs. High-Dose ARB on Renal Markers in Type 2 Diabetes Patients with Stage 1–3 Diabetic Nephropathy Receiving SGLT2i
by Prateek Chopra | July 1, 2026 | Diabetes Conferences | ADA 2026 Study Overview Methods Treatment Groups Baseline Characteristics Renal Outcomes Cardiometabolic Outcomes Safety Findings Clinical Implications High-dose ARB therapy and conventional-dose ARB combined with finerenone demonstrated similar improvements in renal markers over 6 months in patients with diabetic nephropathy receiving SGLT2 inhibitors. Both strategies appear to be viable […]